Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure

OBJECTIVES: Telavancin is approved in Europe for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus when other alternatives are not suitable. The approved European prescribing information contraindicates the use of telavancin in patients with severe renal imp...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Torres, A., Rubinstein, E., Corey, G. R., Stryjewski, M. E., Barriere, S. L.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023300/
https://ncbi.nlm.nih.gov/pubmed/24398339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkt490
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki